290 related articles for article (PubMed ID: 31421019)
21. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.
Hughes DA; Culeddu G; Plumpton CO; Wood E; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot Lacassagne S; Hardwick B; Hickey H; Woo P; Beresford MW; Ramanan AV
Ophthalmology; 2019 Mar; 126(3):415-424. PubMed ID: 30336181
[TBL] [Abstract][Full Text] [Related]
22. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response.
Skrabl-Baumgartner A; Erwa W; Muntean W; Jahnel J
Scand J Rheumatol; 2015; 44(5):359-62. PubMed ID: 25974288
[TBL] [Abstract][Full Text] [Related]
23. Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study.
van Straalen JW; de Roock S; Giancane G; Consolaro A; Rygg M; Nordal EB; Rubio-Pérez N; Jelusic M; De Inocencio J; Vojinovic J; Wulffraat NM; Bruijning-Verhagen PCJ; Ruperto N; Swart JF;
Pediatr Rheumatol Online J; 2022 Nov; 20(1):96. PubMed ID: 36376976
[TBL] [Abstract][Full Text] [Related]
24. Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis.
Breitbach M; Tappeiner C; Böhm MR; Zurek-Imhoff B; Heinz C; Thanos S; Ganser G; Heiligenhaus A
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):171-177. PubMed ID: 27687987
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
Grönlund MM; Remes-Pakarinen T; Kröger L; Markula-Patjas K; Backström M; Putto-Laurila A; Aalto K; Vähäsalo P
Rheumatology (Oxford); 2020 Apr; 59(4):732-741. PubMed ID: 31359057
[TBL] [Abstract][Full Text] [Related]
26. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
[TBL] [Abstract][Full Text] [Related]
27. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
Correll CK; Bullock DR; Cafferty RM; Vehe RK
Clin Rheumatol; 2018 Feb; 37(2):549-553. PubMed ID: 29103180
[TBL] [Abstract][Full Text] [Related]
28. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
[TBL] [Abstract][Full Text] [Related]
29. Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.
Behrens F; Koehm M; Arndt U; Wittig BM; Greger G; Thaçi D; Scharbatke E; Tony HP; Burkhardt H
J Rheumatol; 2016 Mar; 43(3):632-9. PubMed ID: 26669916
[TBL] [Abstract][Full Text] [Related]
30. Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival.
Thiele F; Klein A; Klotsche J; Windschall D; Dressler F; Kuemmerle-Deschner J; Minden K; Foeldvari I; Foell D; Mrusek S; Oommen PT; Horneff G
Rheumatology (Oxford); 2023 Jun; 62(6):2230-2238. PubMed ID: 36222562
[TBL] [Abstract][Full Text] [Related]
31. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
van der Heijde D; Breedveld FC; Kavanaugh A; Keystone EC; Landewé R; Patra K; Pangan AL
J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
[TBL] [Abstract][Full Text] [Related]
32. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
Funk RS; Chan MA; Becker ML
Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
[TBL] [Abstract][Full Text] [Related]
33. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
34. Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
van Dijk BT; Bergstra SA; van den Berg JM; Schonenberg-Meinema D; van Suijlekom-Smit LWA; van Rossum MAJ; Koopman-Keemink Y; Ten Cate R; Allaart CF; Brinkman DMC; Hissink Muller PCE
Pediatr Rheumatol Online J; 2024 May; 22(1):53. PubMed ID: 38730442
[TBL] [Abstract][Full Text] [Related]
35. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
[TBL] [Abstract][Full Text] [Related]
36. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.
Heiligenhaus A; Klotsche J; Tappeiner C; Sengler C; Niewerth M; Liedmann I; Hoeft S; Walscheid K; Lavric M; Foell D; Minden K
Rheumatology (Oxford); 2019 Jun; 58(6):975-986. PubMed ID: 30590748
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial.
Horton S; Jones AP; Guly CM; Hardwick B; Beresford MW; Lee RW; Dick AD; Ramanan AV
Am J Ophthalmol; 2019 Nov; 207():170-174. PubMed ID: 31201796
[TBL] [Abstract][Full Text] [Related]
39. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
40. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
